title: Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.
abstract: With the rationale that a significant reduction of the malignant clone in CML might prolong time to metamorphosis, intensive treatment was given to patients < or = 55 years. Six months of hydroxyurea and high dose interferon-alpha (IFN-alpha) was followed by one to three courses of intensive chemotherapy. Patients who had a donor were allotransplanted and patients who became Ph-negative in bone marrow were autotransplanted. On 1 May 1995, 160 patients were registered in the study. Fifty-one percent of the patients who received six months IFN-alpha and hydroxyurea had a significant Ph-reduction and 5% became Ph-negative. The corresponding figures after two intensive chemotherapy courses were 47 and 28%, respectively. Twenty-seven of 30 autotransplanted patients have been analysed for Ph. Seventeen have relapsed cytogenetically, while ten are Ph-negative 1-64 + months after ABMT. BMT was performed in 59 patients. The actuarial 6-year survival from diagnosis of all 160 registered patients is 68%, which seems to be better than for age-matched historical controls.
authors.affiliation: Department of Medicine, University Hospital, Uppsala, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Simonsson
authors.forename: G
authors.initials: G
authors.lastname: Oberg
authors.forename: M
authors.initials: M
authors.lastname: Björeman
authors.forename: M
authors.initials: M
authors.lastname: Björkholm
authors.forename: J
authors.initials: J
authors.lastname: Carneskog
authors.forename: G
authors.initials: G
authors.lastname: Gahrton
authors.forename: R
authors.initials: R
authors.lastname: Hast
authors.forename: H
authors.initials: H
authors.lastname: Karl
authors.forename: J
authors.initials: J
authors.lastname: Lanng-Nielsen
authors.forename: E
authors.initials: E
authors.lastname: Löfvenberg
authors.forename: C
authors.initials: C
authors.lastname: Malm
authors.forename: I
authors.initials: I
authors.lastname: Turesson
authors.forename: A M
authors.initials: AM
authors.lastname: Udén
authors.forename: L
authors.initials: L
authors.lastname: Vilén
authors.forename: O
authors.initials: O
authors.lastname: Weis-Bjerrum
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003718:Denmark; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D013548:Sweden; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D016898:Interferon-alpha; D006918:Hydroxyurea